Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Development and screening of contrast agents for in vivo imaging of Parkinson's disease.

Neal KL, Shakerdge NB, Hou SS, Klunk WE, Mathis CA, Nesterov EE, Swager TM, McLean PJ, Bacskai BJ.

Mol Imaging Biol. 2013 Oct;15(5):585-95. doi: 10.1007/s11307-013-0634-y.

PMID:
23624948
2.

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Olanow CW, Brundin P.

Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Review.

PMID:
23390095
3.

Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.

Jellinger KA.

Acta Neuropathol. 2003 Sep;106(3):191-201. Epub 2003 Jul 5. Erratum in: Acta Neuropathol (Berl). 2003 Dec;106(6):588.

PMID:
12845452
4.

Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.

Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL.

Brain. 2005 Nov;128(Pt 11):2654-64. Epub 2005 Jul 6.

5.

The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.

Wakabayashi K, Tanji K, Mori F, Takahashi H.

Neuropathology. 2007 Oct;27(5):494-506. Review.

PMID:
18018486
6.

alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8. Epub 2002 Jul 16.

7.

Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology.

Gerard M, Deleersnijder A, Daniëls V, Schreurs S, Munck S, Reumers V, Pottel H, Engelborghs Y, Van den Haute C, Taymans JM, Debyser Z, Baekelandt V.

J Neurosci. 2010 Feb 17;30(7):2454-63. doi: 10.1523/JNEUROSCI.5983-09.2010.

8.

The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia.

Schulz-Schaeffer WJ.

Acta Neuropathol. 2010 Aug;120(2):131-43. doi: 10.1007/s00401-010-0711-0. Epub 2010 Jun 20. Review.

9.

Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.

Junn E, Ronchetti RD, Quezado MM, Kim SY, Mouradian MM.

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2047-52. Epub 2003 Feb 7.

10.

The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease.

Michell AW, Tofaris GK, Gossage H, Tyers P, Spillantini MG, Barker RA.

Cell Transplant. 2007;16(5):461-74.

PMID:
17708336
11.

Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.

Zhou W, Milder JB, Freed CR.

J Biol Chem. 2008 Apr 11;283(15):9863-70. doi: 10.1074/jbc.M710232200. Epub 2008 Jan 30.

12.

In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.

Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai K, Villemagne VL.

Eur J Pharmacol. 2009 Sep 1;617(1-3):54-8. doi: 10.1016/j.ejphar.2009.06.042. Epub 2009 Jul 1.

PMID:
19576880
13.

Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease.

Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, Keshavarzian A.

PLoS One. 2011;6(12):e28032. doi: 10.1371/journal.pone.0028032. Epub 2011 Dec 1.

14.

Mouse models of alpha-synucleinopathy and Lewy pathology.

Sommer B, Barbieri S, Hofele K, Wiederhold K, Probst A, Mistl C, Danner S, Kauffmann S, Spooren W, Tolnay M, Bilbe G, van der Putten H, Kafmann S, Caromi P, Ruegg MA.

Exp Gerontol. 2000 Dec;35(9-10):1389-403.

PMID:
11113617
15.

Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.

Schell H, Hasegawa T, Neumann M, Kahle PJ.

Neuroscience. 2009 Jun 2;160(4):796-804. doi: 10.1016/j.neuroscience.2009.03.002. Epub 2009 Mar 9.

PMID:
19272424
16.

LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.

Guerreiro PS, Huang Y, Gysbers A, Cheng D, Gai WP, Outeiro TF, Halliday GM.

J Mol Med (Berl). 2013 Apr;91(4):513-22. doi: 10.1007/s00109-012-0984-y. Epub 2012 Nov 27.

17.

The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

Spillantini MG, Goedert M.

Ann N Y Acad Sci. 2000;920:16-27. Review.

PMID:
11193145
18.
19.

[Lewy body formation in Parkinson's disease: neurodegeneration or neuroprotection?].

Wakabayashi K.

Rinsho Shinkeigaku. 2008 Nov;48(11):981-3. Review. Japanese.

PMID:
19198138
20.

Evidence against a reliable staging system of alpha-synuclein pathology in Parkinson's disease.

Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK.

Neuropathol Appl Neurobiol. 2009 Feb;35(1):125-6. doi: 10.1111/j.1365-2990.2008.00998.x. No abstract available.

PMID:
19187066
Items per page

Supplemental Content

Write to the Help Desk